Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives
Authors
Keywords
-
Journal
Current Oncology Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-23
DOI
10.1007/s11912-023-01463-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
- (2022) Qin Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival with Cemiplimab in Recurrent Cervical Cancer
- (2022) Krishnansu S. Tewari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: results from the innovaTV 206 study
- (2022) Kan Yonemori et al. CANCER SCIENCE
- Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.
- (2022) Domenica Lorusso et al. JOURNAL OF CLINICAL ONCOLOGY
- Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC).
- (2022) Ignace Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).
- (2022) Manish R. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).
- (2022) Jing Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA32 Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (phase II): Safe and effective in both PD-L1 positive and negative
- (2022) S. Lee et al. ANNALS OF ONCOLOGY
- 520MO Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358
- (2022) A. Oaknin et al. ANNALS OF ONCOLOGY
- Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype
- (2022) Camryn M. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma
- (2022) Lingfang Xia et al. Nature Communications
- Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative
- (2022) Deependra Singh et al. Lancet Global Health
- Intratumoral heterogeneity in cancer progression and response to immunotherapy
- (2021) Ilio Vitale et al. NATURE MEDICINE
- Promises and challenges of adoptive T-cell therapies for solid tumours
- (2021) Matteo Morotti et al. BRITISH JOURNAL OF CANCER
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
- (2021) Robert L Coleman et al. LANCET ONCOLOGY
- Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial
- (2021) Xin Huang et al. Journal for ImmunoTherapy of Cancer
- Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
- (2021) David M. O'Malley et al. GYNECOLOGIC ONCOLOGY
- Pembrolizumab treatment of advanced cervical cancer: updated results from the phase II KEYNOTE-158 study
- (2021) Hyun Chung et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of MEDI0457 and durvalumab for patients with recurrent/metastatic HPV-associated cancers.
- (2021) Van K. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies.
- (2021) Julius Strauss et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
- (2021) Nicoletta Colombo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
- (2021) David M. O'Malley et al. JOURNAL OF CLINICAL ONCOLOGY
- 492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers
- (2021) David O’Malley et al. Journal for ImmunoTherapy of Cancer
- Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
- (2020) Alessandro D. Santin et al. GYNECOLOGIC ONCOLOGY
- Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy
- (2020) Asmita Pal et al. Frontiers in Microbiology
- High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions
- (2020) Soumaya Allouch et al. Frontiers in Oncology
- Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
- (2020) Chunyan Lan et al. JOURNAL OF CLINICAL ONCOLOGY
- TIGIT in cancer immunotherapy
- (2020) Joe-Marc Chauvin et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab for advanced cervical cancer: safety and efficacy
- (2020) Francesca De Felice et al. Expert Review of Anticancer Therapy
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
- (2020) Julius Strauss et al. Journal for ImmunoTherapy of Cancer
- Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
- (2019) K M Heinhuis et al. ANNALS OF ONCOLOGY
- Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
- (2019) Johann S de Bono et al. LANCET ONCOLOGY
- The Intersection between Tumor Angiogenesis and Immune Suppression
- (2019) Osama E. Rahma et al. CLINICAL CANCER RESEARCH
- Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
- (2019) Amir A. Jazaeri et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer
- (2019) S.J. Otter et al. CLINICAL ONCOLOGY
- T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study
- (2019) Stacey L. Doran et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)
- (2019) Juan Francisco Grau et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
- (2019) David S. Hong et al. CLINICAL CANCER RESEARCH
- The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer
- (2018) David Cibula et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma
- (2018) Stephanie Lheureux et al. JAMA Oncology
- A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers
- (2018) Sanja Stevanovic et al. CLINICAL CANCER RESEARCH
- Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
- (2017) Jean-Sebastien Frenel et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
- (2017) Krishnansu S Tewari et al. LANCET
- Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
- (2016) Daniel T. Harris et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Enhancement of T cell recruitment and infiltration into tumours
- (2014) C. Oelkrug et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Improved Survival with Bevacizumab in Advanced Cervical Cancer
- (2014) Krishnansu S. Tewari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
- (2014) P. Muller et al. Cancer Immunology Research
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
- (2013) I. B. Barsoum et al. CANCER RESEARCH
- An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
- (2013) E. C. W. Breij et al. CANCER RESEARCH
- Tissue Factor-Activated Coagulation Cascade in the Tumor Microenvironment Is Critical for Tumor Progression and an Effective Target for Therapy
- (2011) Y. Liu et al. CANCER RESEARCH
- Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
- (2009) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started